Drug Profile
Sym 021
Alternative Names: Anti-PD-1 - Symphogen; S-95016; S095029 - Symphogen; Sym-021Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Symphogen
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Canada (IV, Infusion)